IN THE CLAIMS

Please amend the claims as follows.

1-49. (Canceled)

50. (New) A drug-oligomer conjugate having the formula:

$$D\text{-}H_p$$

wherein D is a therapeutic drug moiety;

H is a PEG polymer having from 1 to 10 PEG units; and

p is a number from 1 to the maximum number of covalent bonding sites at which -H can form a bond with D.

51. (New) The drug-oligomer conjugate of claim 50, wherein H is a PEG polymer having from 2 to 7 PEG units.

52. (New) The drug-oligomer conjugate of claim 50, wherein H is a PEG polymer having 2, 3, 4 or 5 PEG units.

53. (New) The drug-oligomer conjugate of claim 50, wherein H is a PEG polymer having 3 PEG units.

54. (New) The drug-oligomer conjugate of claim 50, wherein the D-H bonds are non-hydrolyzable.

55. (New) The drug-oligomer conjugate of claim 50, wherein the D-H bonds are selected from the group consisting of carbamate, amide and secondary amine.

56. (New) The drug-oligomer conjugate of claim 50, wherein D is a biologically active polypeptide.

57. (New) The drug-oligomer conjugate of claim 56, wherein the biologically active polypeptide has at least one available moiety for conjugation selected from the group consisting of XNH_2; -OH and XSH; and wherein at least one of the available moieties is conjugated to the H moiety.

58. (New) The drug-oligomer conjugate of claim 50, wherein D is selected from the group consisting of insulin, insulin lispro, and a functional equivalent of insulin.

59. (New) The drug-oligomer conjugate of claim 58, wherein H is a PEG polymer having from 2 to 7 PEG units.

60. (New) The drug-oligomer conjugate of claim 58, wherein H is a PEG polymer having 2, 3, 4 or 5 PEG units.

61. (New) The drug-oligomer conjugate of claim 58, wherein H is a PEG polymer having 3 PEG units.

62. (New) A pharmaceutical composition comprising the drug-oligomer conjugate of claim 50, in association with a pharmaceutical carrier.

63. (New) A pharmaceutical composition comprising the drug-oligomer conjugate of claim 58, in association with a pharmaceutical carrier.

64. (New) A method of delivering a drug-conjugate to a situs of a subject, comprising administering to the subject an effective amount of a drug-oligomer conjugate according to claim 50.

65. (New) A method of delivering a drug-conjugate to a situs of a subject, comprising administering to the subject an effective amount of a drug-oligomer conjugate according to claim 58.

66. (New) A drug-PEG conjugate having the formula:

$$D\text{-}H_p$$

wherein D is selected from the group consisting of insulin, insulin lispro, and a functional equivalent of insulin;

H is a PEG polymer having from 1 to 10 PEG units; and

p is a number from 1 to the maximum number of covalent bonding sites at which -H can form a bond with D,

wherein the drug-PEG conjugate has enhanced activity in comparison with a corresponding unconjugated insulin molecule, unconjugated insulin lispro molecule or unconjugated functional equivalent thereof.

67. (New) A method of delivering the drug-PEG conjugate of claim 66 to a situs of a subject, comprising administering to the subject an effective amount of the drug-PEG conjugate.

68. (New) A pharmaceutical composition comprising the drug-oligomer conjugate of claim 66, in association with a pharmaceutical carrier.